Crossmark

Safety and Efficacy of Brodalumab for the Management of Patients With Moderate-to-Severe Psoriasis After 1 Year of Therapy and its Efficacy in Obese Patients: A Single-Center Real-World Clinical Practice Study

Crossref DOI link: https://doi.org/10.1016/j.ad.2026.104614

Published Print: 2026-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Carmona-Olveira, A. https://orcid.org/0000-0002-0181-9478
Suárez-Pérez, J.A.

Garriga-Martina, G.

Herrera Acosta, E.
Funding

Funding for this research was provided by:

Universidad de Málaga
License Information

Text and Data Mining valid from 2026-06-01

Text and Data Mining valid from 2026-06-01

Version of Record valid from 2026-03-11
More Information

This article is maintained by: Elsevier

Article Title: Safety and Efficacy of Brodalumab for the Management of Patients With Moderate-to-Severe Psoriasis After 1 Year of Therapy and its Efficacy in Obese Patients: A Single-Center Real-World Clinical Practice Study

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2026.104614

Content Type: simple-article

Copyright: © 2026 AEDV. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below